![\"Pure](\"https:\/\/www.send2press.com\/wire\/images\/22-0215-pure-and-vall-800x600.jpg\")
<\/em><\/p>\nThe research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.<\/p>\n
\u201cThis collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification,\u201d Dr. Bestard stated.<\/p>\n
\u201cToday, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management,\u201d said Dr. Buchli.<\/p>\n
Steve Mayer MD, Chief Medical Officer at PTS stated, \u201cWe\u2019re very excited about the potential of this technology because it allows a very early diagnostic view of an individual\u2019s risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values.\u201d<\/p>\n
About Pure Transplant Solutions, LLC<\/strong><\/p>\n Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https:\/\/www.puretransplant.com\/<\/a>.<\/p>\n About Pure Protein, LLC<\/strong><\/p>\n Pure Protein, L.L.C.<\/a> is a biotechnology company funded and managed by Emergent Technologies, Inc.<\/a> that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.<\/p>\n
![https:\/\/www.Send2Press.com\/300dpi\/22-0215-s2p-ptransplant-logo-300dpi.jpg<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d’Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.<\/p>\n","protected":false},"author":8776,"featured_media":78954,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[602,755,12804,334,1,61,499,17638,55],"tags":[14508,15219,17710],"class_list":["post-79006","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology-news","category-alliances-news","category-ap","category-austin-news","category-business-news","category-health-medical-news","category-medical-research-news","category-spain-business","category-texas-news","tag-human-leukocyte-antigen","tag-transplant-rejection","tag-vall-dhebron-barcelona-hospital-campus","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":3825,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/79006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/8776"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=79006"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/79006\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/78954"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=79006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=79006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=79006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}](\"https:\/\/www.Send2Press.com\/300dpi\/22-0215-s2p-ptransplant-logo-300dpi.jpg\"){kind=link}